Contractile force in electrically stimulated human atrial pectinate muscle (PDE3 receptor)

Drug Discovery Assay – reference number: B050

Overview

Assay Description

This assay assesses whether test compounds cause an increase in contractile force in electrically stimulated human atrial muscle with milrinone as a reference compound. Additional analyses can be undertaken to report on the rate of both contraction (dF/dt) and rate of relaxation (–dF/dt).

Pectinate muscles are mainly located in the right atrium of the heart. The muscles function to allow the atria to dilate without increased wall stress and also allow an increase in the volume of the atria.

Testing Information

Introduction

The specific results that will be provided are the effects of increasing concentrations of test articles on the contractile state of isolated human atrial pectinate muscle.

Turnaround Time

6 weeks from sample receipt for n = 3 donors.

Timelines are a guide based on REPROCELL Biopta’s standard tissue criteria; any client-imposed deviations to the standard tissue criteria can alter the project timelines.

Test Article Requirements

Test article(s) to be provided by the Sponsor in storable aliquots at required test concentrations with information on diluent vehicle used. Stock solutions are prepared in distilled water unless otherwise requested. Bath volumes are 5mL; sponsor to provide sufficient test article to run the entire study.

Suggested Testing

In duplicate at 6 concentrations.

Study Outline

Rationale and Experimental Design

This assay assesses whether test compounds cause an increase in contractile force in electrically stimulated human atrial muscle with milrinone as a reference compound. Additional analyses can be undertaken to report on the rate of both contraction (dF/dt) and rate of relaxation (–dF/dt).

Exclusion Criteria

No specific exclusion criteria are in place other than to reject macroscopically diseased/necrotic tissue. Furthermore, tissues which do not respond to the standard pharmacology checks will be excluded.

Standardisation and Qualification

All individual muscle preparations are initially processed through standardisation and qualification procedures to ensure functionality, prior to starting the study protocol.

Muscle preparations are processed through a standardisation procedure to reduce signal variability prior to electrical field stimulation and pharmacological intervention. This ensures that muscle preparations are maintained under appropriate physiological tension throughout the experiments.

Following standardisation, muscle preparations are subjected to an electrical field stimulation (EFS) voltage curve. This process determines the optimal EFS settings to be utilised during the study protocol.

Test tissues are then washed, and the EFS responses allowed to settle to steady baseline levels.

Muscle preparations which pass the standardisation and qualification pass/fail criteria will then progress to the study protocol/

Ventricular Muscle Contractility Assays

To assess their ability to modulate EFS mediated cardiac contractility, 6 point cumulative concentration response curves (CCRC’s) will be performed for each test item. These CCRC’s will be performed upon a steady baseline EFS response. A positive control compound and representative test article vehicle CCRC will also be run to allow direct comparison with test articles.

An example of the conditions assessed for 3 test articles are detailed below (each condition will be run in duplicate muscle preparations):

• Representative test article vehicle CCRC

• Positive control CCRC

• Test article 1 CCRC

• Test article 2 CCRC

• Test article 3 CCRC

Analysis

Responses shall be expressed as % change from baseline EFS response. Statistical analysis (where appropriate) will be performed using GraphPad Prism, with the results being shown in graphical form in the final report.

Back to the Drug Discovery Assay Catalog »